Member Info for 86KB

We are holding ongoing and progressive discussions with the FDA for US regulatory approval of CARDIO inCode® to significantly accelerate growth. Commensurate with the revenue growth and ongoing operational efficiencies, we are now moving the business towards breakeven.

I think this will see double digits very soon.

NT to buy at 4.2, certainly background buying going on here.

Yes building back up, getting 12.7p to buy now. Think that maybe the last time we see 11s. Possibly a strong bounce this afternoon if not then tomorrow. 23M traded so far. GLA.

Zak Mirs

https://youtu.be/tSUsuxcuplA?feature=shared

Yesterdays stock house

https://youtu.be/f4U-96wP_fA?feature=shared

Latino the tr1 holder there keeps trading renx hence why the drop there.

Look how we have held even with speeding ticket, other companies would have dropped much lower and lost its gains. That itself is telling, someone loading ahead of news. Free float is tiny. I took advantage of this drop and I am sure many others would have.

Popeye Good morning to you too. Yes there won't be further dilution after all the warrants have been exercised so nothing to hold it back. Pullbacks are expected at some point and these warrants/profit takers helped with that.

Should see these get going again at some point. But this board is becoming infested. Dyor everyone and don't fall for the naysayers agenda.

Simple the shares have been moving because its undervalued as mentioned in the rns and because of the interims which they expect increase in revenue and breakeven. Along with FDA news and collaboration. They are the reasons for the rise.

They failed my trade 3 times on that drop. Rns looks good back up we go

The board believes the shares remain undervalued. The Company reconfirms its trading and operation position set out in the trading update of 26 August 2025 with FDA De Novo discussions continuing to progress and work ongoing to close out the remaining deficiencies. Collaboration discussions on potential US and EU test distribution are progressing with a major distributer. The Company looks forward to updating the market at its interim results on Tuesday, 30 September 2025.

Certianly looking good gere, something is drriving this and we will find out soon enough. Interims out on 30th September and presentation on 2nd October. I am sure they will have lots to talk about, FDA and collaboration.

Both feet into 5s, we could possibly see 8.50p today. Lets see.

Yep 5p going to get taken out

Yep only 133m shares (44.48%) available out of the 286m shares in issue.

Https://www.proactiveinvestors.co.uk/companies/news/1078596/imaging-biometrics-strikes-deal-to-commercialise-advanced-brain-scan-software-1078596.html?viewSource=TwitterUK

Not much free float about, hence why keeps going NT to buy.

Octopus Investments Limited 52,877,293 18.43%

Maven Income and Growth VCT1 37,388,329 13.03%

Santi – 1990 SL 35,595,587 12.41%

Foresight Group LLP 10,236,864 3.57%

Jordi Puig1,2 14,737,636 5.14%

Matthew Walls 12,235,473 4.26%

Sergio Olivero2 7,417,243 2.59%

Huon Gray 905,405 0.32%

Felix Freuh 100,000 0.03%

Popeye do you remember what they did when released warrants rns last time? Pretty much the same as this morning. They took it down, filled orders, then took it back up and ended up making a new high on that day.

If they mention they are breakeven at the next set of results then expect to see a big run.

I think positions are being taken ahead of interims. They are expected to have year on year growth. Not only that would think collaboration news and FDA approval would take these much higher. Mcap is tiny with low free float.

Current trading and Outlook

· For the first four months of FY25 consolidated revenues were 20% higher than same period in 2024

· During 2025, the Company expects to complete the following key deliverables:

o Significant increase in year-on-year revenues, improving margins with a substantive reduction in EBITDA losses continuing to move the Company towards breakeven

o Commercial expansion of LIPID inCode® and scale-up of CARDIO inCode® across the US market

o Implementation of LIPID inCode® and CARDIO inCode® testing in leading US healthcare institutions and State-based healthcare systems

o Finalise discussions with FDA and agree De Novo approval pathway for CARDIO inCode®

o Expansion of the NHS programme for LIPID inCode® and introduction of CARDIO inCode®

o Expansion of the MVZ Uniklinikum, Germany collaborative programme to provide LIPID inCode® testing for its patients

o Build on EU partnerships and finalise ongoing collaborative discussions

o Growth of ROCA® trust adoption in the NHS and expansion in EU

o Continued strengthening of the commercial, marketing and selling teams to support revenue growth

On news would say 20-26p, but before that test January high at 8.5p.